AI Article Synopsis
- Defibrotide (DFT) is studied as a potential treatment for veno-occlusive disease (VOD) and its impact on neutrophil engraftment in pediatric hematopoietic stem cell transplantation (HSCT) patients.
- A retrospective analysis of 44 pediatric patients revealed significant differences in the time to neutrophil and white blood cell engraftment between those receiving DFT prophylaxis and those who did not.
- The findings suggest that DFT prophylaxis may delay the engraftment of polymorphonuclear neutrophils in children undergoing HSCT.
Article Abstract
Introduction: In recent years, defibrotide (DFT) has emerged as a promising therapy for veno-occlusive disease (VOD). The aim of this study was to investigate whether DFT prophylaxis affects neutrophil engraftment in patients undergoing hematopoietic stem cell transplantation (HSCT).
Methods: A cohort of 44 consecutive pediatric patients who underwent HSCT was retrospectively analyzed to see the role of DFT on engraftment. Patients were assigned into two groups based on the use or non-use of prophylaxis with DFT.
Results: The mean time to engraftment was statistically different between the two groups for both polymorphonuclear neutrophils (PMN) and white blood cells.
Conclusion: Our study supports the hypothesis that prophylaxis with DFT for VOD leads to a delay to the engraftment of PMN in pediatric patients that underwent HSCT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12325-015-0203-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bronchial structural changes analyzed with three-dimensional computed tomography correlate with severe acute graft-versus-host disease after allogenic hematopoietic stem cell transplantation.
Ann Hematol
January 2025
Third Department of Internal Medicine, Yamaguchi University Hospital, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan.
Severe acute graft-versus-host disease (GVHD) can occur during allogeneic hematopoietic stem cell transplantation (allo-HSCT), causing considerable morbidity and mortality. Although several biomarkers have been reported for predicting acute GVHD, they are often difficult to measure in routine clinical practice. Recently, three-dimensional computed tomography (3D-CT) has been used to quantify the detailed bronchial structure, which might correlate with acute GVHD.
View Article and Find Full Text PDFSenescent cell-derived extracellular vesicles inhibit cancer recurrence by coordinating immune surveillance.
Cancer Res
January 2025
Oregon Health & Science University, Portland, OR, United States.
Senescence is a non-proliferative, survival state that cancer cells can enter to escape therapy. In addition to soluble factors, senescence cells secrete extracellular vesicles (EVs), which are important mediators of intercellular communication. To explore the role of senescent cell-derived EVs (senEVs) in inflammatory responses to senescence, we developed an engraftment-based senescence model in wild-type mice and genetically blocked senEV release in vivo, without significantly affecting soluble mediators.
View Article and Find Full Text PDFImpact of Granulocyte Colony-Stimulating Factor (G-CSF) on Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation: Does Speeding Up Neutrophil Engraftment Make a Difference?
Transplant Direct
February 2025
Department of Medicine, University of Toronto, Toronto, ON, Canada.
Background: Despite decades of post-allogeneic hematopoietic cell transplantation (HCT) growth factor utilization, its role remains undefined, leading to ongoing debates and research. The theoretical impacts of growth factors have been challenged in numerous studies.
Methods: In this retrospective cohort study conducted at the Princess Margaret Cancer Centre, we analyzed the clinical outcomes of 509 patients who underwent allogeneic HCT between May 1, 2019, and May 31, 2022.
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation: A Randomized Clinical Trial.
JAMA Oncol
January 2025
Division of Hematologic Malignancies, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Importance: Although sharing care with local oncologists after allogeneic hematopoietic cell transplantation (HCT) has been proposed for patients living far from HCT centers, it is not known whether a shared strategy is safe or improves patient quality of life (QOL).
Objective: To determine the efficacy and safety of sharing follow-up care after HCT between the HCT specialty center and local oncologists.
Design, Setting, And Participants: This was a multicenter collaborative randomized clinical trial of patients undergoing HCT at Dana-Farber Cancer Institute (DFCI)-a high volume HCT center in Boston (Massachusetts)-and 8 local oncology practices.
[Disseminated toxoplasmosis after cord blood transplantation diagnosed at autopsy].
Rinsho Ketsueki
January 2025
Department of Hematology and Oncology, Tokai University School of Medicine.
A 54-year-old woman underwent cord blood transplantation in second remission of acute myeloid leukemia. She tested positive for anti-toxoplasma IgG antibody before transplantation. After neutrophil engraftment, she complained of foggy vision, but brain MRI showed no abnormality.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!